Truist Financial Maintains Si-Bone(SIBN.US) With Buy Rating, Cuts Target Price to $16
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
Truist Financial Maintains Si-Bone(SIBN.US) With Buy Rating, Announces Target Price $16
SI-BONE Analyst Ratings
Truist Lowers Price Target on SI-BONE to $16 From $18, Keeps Buy Rating
SI-BONE, Inc. Announces First-In-Patient Procedures With FDA Breakthrough Device for Pelvic Fracture Fixation
SI-BONE Insiders Sell US$2.3m Of Stock, Possibly Signalling Caution
Piper Sandler Maintains Si-Bone(SIBN.US) With Buy Rating, Maintains Target Price $25
CRL Stock May Benefit From New Neuroscience Research Collaboration
SI-BONE (NASDAQ:SIBN Shareholders Incur Further Losses as Stock Declines 8.8% This Week, Taking Three-year Losses to 33%
Morgan Stanley Maintains Si-Bone(SIBN.US) With Buy Rating, Maintains Target Price $19
Morgan Stanley analyst Drew Ranieri maintains $Si-Bone(SIBN.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 39.8% and a
Buy Rating Justified: SI-Bone's Growth Potential and Market Expansion Opportunities
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
SI-BONE Up Nearly 10%, on Pace for Largest Percent Increase Since February 2023 -- Data Talk
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024
FDA Grants Clearance for SI-Bone's Pelvic Fixation System
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Express News | SI-BONE, Inc. Receives 510(K) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
SI-BONE Second Quarter 2024 Earnings: Beats Expectations